

Patient Organization Funding ^[1]

Novartis is committed to open dialogue and transparent exchange of information with patient organizations as detailed in our Commitment to Patients and Caregivers. We see patient groups as a key partner in our decision-making throughout the product lifecycle. We believe that incorporating the patient perspective in our decision-making can help us to develop better products for the benefit of patients.

Novartis engages with patient organizations in recognition of their unique skills, expertise and perspectives. We pledge to fully respect their independence and integrity. Patient organizations are neither required nor encouraged to promote or endorse Novartis products and services. We do not initiate or drive the initiation of a new patient organization and strive not to be the sole funder of any patient organization. When engaging patient organization representatives as speakers, Novartis will compensate them for their time and expenses according to local laws and regulations on a fair market value basis.

Novartis annually discloses monetary and non-monetary support to patient organizations around the globe by June 30 every year in compliance with the [Code of Practice](#) ^[2] on Relationships between the Pharmaceutical Industry and Patient Organizations set by the European Federation of Pharmaceutical Industries and Associations ([EFPIA](#) ^[3]). Novartis endorses the EFPIA Code and other relevant industry codes ^[4] to help enable its relationships with patient organizations to take place in an ethical and transparent manner.

- [Download the 2018 report \(PDF 3.0 MB\)](#) ^[5]
- [Download the 2017 report \(PDF 0.7 MB\)](#) ^[6]
- [Download the 2016 report \(PDF 0.3 MB\)](#) ^[7]

[Read our position on patient group interaction and support \(PDF 0.2 MB\)](#) ^[8]

[Read our position on Global ToV reporting for Patient Organizations 2018 \(PDF 0.6 MB\)](#) ^[9]

[Read the EFPIA Code](#) ^[10]

Novartis is committed to supporting patient groups responsibly.

Source URL: <https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/patient-group-funding>

Links

[1] <https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/patient-group-funding>

[2] <https://www.efpia.eu/relationships-codes/>

[3] <https://www.efpia.eu/>

[4] <https://www.phrma.org/codes-and-guidelines/phrma-principles-on-interactions-with-patient-organizations>

[5] <https://www.novartis.com/sites/www.novartis.com/files/patient-support-web-report-2018.pdf>

- [6] <https://www.novartis.com/sites/www.novartis.com/files/patient-support-web-report-2017.pdf>
- [7] <https://www.novartis.com/sites/www.novartis.com/files/patient-support-web-report-2016.pdf>
- [8] <https://www.novartis.com/sites/www.novartis.com/files/novartis-position-on-collaborating-with-patient-organizations.pdf>
- [9] <https://www.novartis.com/sites/www.novartis.com/files/novartis-patient-organization-methodological-note.pdf>
- [10] <https://efpia.eu/relationships-codes/>